Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 46.68% is 149% above its 5-year average of 18.75%, near the high end of its 5-year range (3.92%–46.68%).
As of the fiscal period ended Friday, July 3, 2026. 24.85% above its 12-month average of 37.39%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-07-03): 46.68%.
RETURN ON EQUITY (ROE)
46.68%
RETURN ON EQUITY (ROE) AVG TTM
37.39%
RETURN ON EQUITY (ROE) AVG 3Y
25.01%
RETURN ON EQUITY (ROE) AVG 5Y
18.75%
RETURN ON EQUITY (ROE) AVG 10Y
23.93%
RETURN ON EQUITY (ROE) AVG 15Y
26.16%
RETURN ON EQUITY (ROE) AVG 20Y
20.01%
CURRENT VS TTM AVG
+24.85%
CURRENT VS 3Y AVG
+86.63%
CURRENT VS 5Y AVG
+148.99%
CURRENT VS 10Y AVG
+95.06%
CURRENT VS 15Y AVG
+78.43%
CURRENT VS 20Y AVG
+133.31%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+211.11%
vs the sector median at left
Exelixis, Inc.
Market Cap
$14.66B
Return on Equity (ROE)
46.68%
TTM Avg
37.39%
3Y Avg
25.01%
5Y Avg
18.75%
Market Cap
$14.69B
Return on Equity (ROE)
-8.40%
TTM Avg
-2.13%
3Y Avg
6.32%
5Y Avg
9.65%
Market Cap
$14.63B
Return on Equity (ROE)
19.10%
TTM Avg
13.95%
3Y Avg
12.03%
5Y Avg
15.14%
Market Cap
$14.54B
Return on Equity (ROE)
19.59%
TTM Avg
2.71%
3Y Avg
2.32%
5Y Avg
1.25%
Market Cap
$15.07B
Return on Equity (ROE)
29.88%
TTM Avg
23.51%
3Y Avg
17.50%
5Y Avg
13.68%
Market Cap
$14.04B
Return on Equity (ROE)
52.97%
TTM Avg
246.13%
3Y Avg
150.31%
5Y Avg
84.65%
Market Cap
$13.81B
Return on Equity (ROE)
-135.89%
TTM Avg
-138.84%
3Y Avg
-281.35%
5Y Avg
-216.26%
Market Cap
$13.11B
Return on Equity (ROE)
N/A
TTM Avg
35.81%
3Y Avg
39.37%
5Y Avg
-92.14%
Market Cap
$13.01B
Return on Equity (ROE)
288.13%
TTM Avg
385.62%
3Y Avg
306.57%
5Y Avg
252.70%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exelixis, Inc. (EXEL) | $14.66B | 46.68% | 37.39% | 25.01% | 18.75% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | -8.40% | -2.13% | 6.32% | 9.65% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 19.10% | 13.95% | 12.03% | 15.14% |
| Jazz Pharmaceuticals plc (JAZZ)vs › | $14.54B | 19.59% | 2.71% | 2.32% | 1.25% |
| Solventum Corporation (SOLV)vs › | $15.07B | 29.88% | 23.51% | 17.50% | 13.68% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | 52.97% | 246.13% | 150.31% | 84.65% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | -135.89% | -138.84% | -281.35% | -216.26% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | N/A | 35.81% | 39.37% | -92.14% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 288.13% | 385.62% | 306.57% | 252.70% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 7.78% | 17.97% | 19.27% | 21.22% |
ROE
46.7%
ROA
34.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-03 | 46.68% |
| 2026-04-03 | 43.05% |
| 2026-01-02 | 36.21% |
| 2025-10-03 | 31.37% |
| 2025-07-04 | 29.62% |
| 2025-04-04 | 30.20% |
| 2024-12-31 | 23.23% |
| 2024-09-27 | 20.52% |
| 2024-06-28 | 16.51% |
| 2024-03-29 | 9.64% |
| 2023-12-31 | 9.18% |
| 2023-09-29 | 3.92% |
| 2023-06-30 | 6.50% |
| 2023-03-31 | 6.02% |
| 2022-12-31 | 7.33% |
| 2022-09-30 | 12.35% |
| 2022-07-01 | 11.40% |
| 2022-04-01 | 12.99% |
| 2021-12-31 | 10.45% |
| 2021-10-01 | 7.78% |
| 2021-07-02 | 4.60% |
| 2021-04-02 | 3.39% |
| 2020-12-31 | 5.95% |
| 2020-10-02 | 8.21% |
| 2020-07-03 | 15.36% |
| 2020-04-03 | 16.81% |
| 2019-12-31 | 19.04% |
| 2019-09-27 | 38.18% |
| 2019-06-28 | 43.10% |
| 2019-03-29 | 46.93% |
| 2018-12-31 | 53.60% |
| 2018-09-28 | 40.23% |
| 2018-06-29 | 41.71% |
| 2018-03-30 | 37.83% |
| 2017-12-31 | 54.12% |
| 2017-09-29 | 63.20% |
| 2017-06-30 | 39.19% |
| 2017-03-31 | 2.94% |
| 2016-12-31 | -83.44% |
| 2016-09-30 | -478.69% |
| 2014-03-28 | -384.22% |
| 2013-12-31 | -369.52% |
| 2013-09-27 | -170.38% |
| 2013-06-28 | -97.74% |
| 2013-03-29 | -65.22% |
| 2012-12-31 | -49.81% |
| 2012-09-30 | -14.42% |
| 2012-06-29 | 62.11% |
| 2012-03-30 | 58.21% |
| 2011-12-31 | 83.52% |
| 2011-09-30 | 377.70% |
| 2008-03-28 | -259.54% |
| 2007-12-31 | -119.84% |
| 2007-09-28 | -108.07% |
| 2007-06-29 | -521.34% |
| 2007-03-30 | -259.47% |
| 2006-12-31 | -193.17% |
| 2006-03-31 | -588.72% |
| 2005-12-31 | -251.63% |
| 2005-09-30 | -199.99% |
| 2005-06-30 | -408.00% |
| 2005-03-31 | -410.21% |
| 2004-12-31 | -270.86% |
| 2004-09-30 | -134.63% |
| 2004-06-30 | -99.34% |
| 2004-03-31 | -74.68% |
| 2003-12-31 | -58.69% |
| 2003-09-30 | -50.34% |
| 2003-06-30 | -45.05% |
